Mobilise-D and Cure Parkinson’s UK in strategic partnership to accelerate the translation of research into clinical practice
We are excited to announce our strategic partnership with Cure Parkinson’s UK, working closely together to bring our research and clinical studies closer to patients and the public. We asked Helen Matthews, Deputy CEO of Cure Parkinson’s, to share with us her vision about the benefits of the research and clinical trials in Parkinson’s Disease, and the collaboration with Mobilise-D.
Webinar series: Mobilise-D presents its four patient cohorts
We start the autumn Mobilise-D Webinars series presenting the needs, technologies, protocols and patient perspectives for each of our four cohorts engaged in the Mobilise-D studies.
NEW VIDEO: The Mobilise-D journey!
Watch how Mobilise-D develops innovative digital technology to measure mobility in daily life, thereby transforming clinical research and contributing to personalised health.
“The End” of Work Package 2 – Algorithm development and technical validation
The work on algorithm development and technical validation has come to an end. We cannot believe it’s been three years already!
Webinar recordings available on our YouTube channel
We’ve had the first two public webinars as part of our ongoing Mobilise-D webinar series, and it has been a great success! The recordings are now available on our YouTube channel.
Grosshansdorf is the first Mobilise-D site to reach their target number of participants in the Clinical Validation Study
We are very proud to announce that the Pulmonary Research Institute (PRI) in Grosshandorf, Schleswig-Holstein, Germany, is the first clinical site in our ongoing Clinical Validation Study that has reached their target number of included participants. They just reported that participant #140 has entered the Mobilise-D study, thereby completing their target for the COPD (Chronic Obstructive Pulmonary Disease) cohort.
The Mobilise-D Public Webinar Series starts in February 2022
We have designed the first series of five webinars, twice a month (February to April 2022, 90 minutes each) where our team will present and discuss cutting-edge thinking on mobility assessments, our technical validation approach, and examples of data and tools used.
Falling down is easy, getting up is difficult
Episode 4: Tova Gur Arieh tries to live a full life and do daily things with as much energy as anyone – despite severe challenges. She loves to be with her family, see friends, and play with her grandchildren on the floor. Getting up from the floor has become more of a challenge in recent years. Two and a half years ago, Tova was diagnosed with Parkinson’s disease (PD) and her walking became more difficult and she had some falls. She refused to let the diagnosis keep her down on the floor.
Mobilise-D links with Voice Global to promote global patient engagement!
We are pleased to announce that Mobilise-D is now using the Voice Global platform as part of our Patient and Public Involvement and Engagement (PPIE) activities.
Mobilise-D Patient and Public Information Pack
The PPAG has worked with some of our researchers to develop a document that explains the project and its aims to anyone who may be interested in it.
Novartis job opportunity for analysis of wearable sensor data for Digital Mobility Outcomes
Novartis is now looking for a Digital Data Scientist to join their group and participate in their ground-breaking medical research activities that redefine the grammar for medicine in the post-genome era.
Episode 4: The Cyclone Challenge – Mobiliser Raising Money for PD UK
The day had finally arrived. The day for the Cyclone Challenge Ride. Saturday, July 03, the day mobiliser Alison Yarnall and her friend Naomi were going to ride their bicycles for 108 miles (173,8 km). The day they wanted to raise money for a good cause. The day they raised money for Parkinson’s UK.
Mobilise-D Workshop at the IEEE BHI-BSN Conference: Real-world Digital Mobility Assessment
Our Mobilisers Andrea Cereatti, Silvia Del Din and Felix Kluge will organize a workshop on “Real-world digital mobility assessment” at the virtual IEEE International Conference on Biomedical and Health Informatics at the end of July.
ISB2021 Mobilise-D Tutorial: Translating Movement Analysis Beyond the Laboratory with Wearable Sensors
The Congress of the International Society of Biomechanics (ISB) will be held from July 25-29, 2021. On Sunday, July 25, 09:30-11:30, our Mobilise-D colleagues Andrea Cereatti, Silvia Del Din, and Kamiar Aminian will have a tutorial: “To wear or not to wear? Translating Movement Analysis Beyond the Laboratory with Wearable Sensors”.
Episode 3: Making a difference in people’s lives – Silvia Del Din awarded a NUAcT Fellowship.
Our Mobilise-D colleague Dr. Silvia Del-Din has always been fascinated by research and the idea of “making a difference in people’s lives”. Here she explains her role in Mobilise-D, her new NUAcT fellowship at Newcastle University, and her perspective on how remote monitoring can revolutionize healthcare.
Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective
Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in. On February 15, 2021, IMI Neuronet hosted an online meeting on health technology assessment (HTA) and regulatory interactions. The discussions were based on the experiences of three different IMI projects that are developing digital endpoints for use in clinical trials, including Mobilise-D. To support the discussions, three international HTA experts that represent different organisations were invited to provide their perspectives on several important issues.
IMI article about our Digital Health Catalyst initiative
The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and application in the area of real-world digital measurements.
When life gives you lemons, make Lemon Drizzle cake!
Real World Stories – Episode 3: “My balance is elusive advanced Multiple Sclerosis (MS). Always optimistic. Want to walk at least 25 times a month for eight months #2021Walkathon. Love my Travelscoot (The Trike)”. This is the Twitter bio of “Patrick Burke, I walk very slowly”, the inspiration behind the third episode of our Real World Stories.
An INSIGHT into public engagement: Interview with PhD student Cameron Kirk
In the Spotlight: This is exactly what drove me to apply for the INSIGHTS doctoral public lecture prize at Newcastle University, UK. This prize was competed by all post-graduate students within the university, and we had to create a presentation that explains our PhD research to the public, in as clear a manner as possible. I was a runner up for the award, and here is an excerpt from an interview I had with the INSIGHTS team, in the build-up for the event.
It’s a kind of magic: the validation study has been Mobilise-D against all odds
We invited one of our Mobilisers working in WP2 Algorithm Development and Technical Validation, Kirsty Scott, to share some of the daunting yet exciting experiences of being part of the team and how they are managing to conduct the Technical Validation Study in Mobilise-D in COVID-19 times.
– It’s great to exercise myself together with my groups
Real World Stories – Episode 2: “I’ve always been passionate about exercising; I’ve taken a lot of instructor courses. To be able to work as a volunteer, as we all do in Strong and Steady, is a great offer and again, with MS, it’s great to exercise me together with my groups. That’s quality of life!”
Mobilise-D and IDEA-FAST join forces to strengthen research and development of digital biomarkers
From January 2021 onwards, Mobilise-D and IDEA-FAST, two ongoing EU Innovative Medicines Initiatives projects, will join forces to increase the impact and the benefits of digital health technologies developed by both projects.
This coming Friday Abolfazl Soltani, one of our Mobilisers from EPFL, Switzerland, will have the public defense of his PhD thesis. This will be a more popular presentation of his work for the general public.
In the first year of Mobilise-D, we asked the European Medicines Agency (EMA) for qualification advice for Digital Mobility Outcomes (DMOs). EMA just published their letter of support that publicly endorses our initial stage in the wider objective of the Mobilise-D Consortium to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of mobility performance in regulatory drug trials. We have now got support to continue our work towards regulatory approval of DMOs as biomarkers!
Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure, or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation study testing will continue despite the 2nd lockdown in the UK.
[VIDEO] A “Normal” day at the UNISS lab
Measuring real-world mobility outside the lab with a Gold Standard system is no mean feat. Our Mobilise-D partners at the University of Sassari in Sardinia (UNISS) have developed the INDIP system which is currently being used in the ongoing technical validation study. But for the INDIP to work smoothly at our test sites in the UK, Germany, and Israel, a lot of hard work is necessary from many people. In this video, you get a small peek behind the scenes at UNISS.
– I felt mobilise-d
Real World Stories – Episode 1: Mobility – how well people walk – is an important marker of health. With advanced age, as well as disease and injury, mobility challenges often become prominent. The COVID-19 breakout and the subsequent lockdowns all over the world put severe restrictions on everyone’s mobility. However, as it turns out, the effect on people’s mobility has not only been negative. For Gottfried Koch (69), who has a previous history of heart disease, the lockdown, combined with watching our video was a small turning point in his life.
[VIDEO] Introduction to Mobilise D Clinical Trials
Being able to remotely monitor patients’ mobility in their natural environment is a major advantage, both in lockdown and in general. To meet the societal need for better mobility assessment, Mobilise-D will follow up the ongoing technical validation study with a large-scale clinical study that will include 2400 patients from four different cohorts across different sites in Europe.
[VIDEO] Why Mobility Matters
Mobility is often said to be a sixth vital sign, just as important as other vital signs such as blood pressure and heart rate, and the key to independence in our daily life. But what does mobility actually mean for people? And what happens when they experience mobility loss?
We asked several people what the importance of mobility is for them, and what the impact was when they experienced mobility loss. Here are some of their answers.
[VIDEO] What is Mobilise-D – Mobility as a vital sign
Prof. Lynn Rochester and Dr. Ronenn Roubenoff explain how mobility is a vital sign and the benefits of being able to measure people’s mobility in a reliable way. To achieve a robust digital mobility outcome, Mobilise-D will first have to overcome a few challenges. More about this in the video.
[VIDEO] Mobilise-D in COVID-19 times: Why Mobilise-D matters – now more than ever!
Mobilise-D technology for remote monitoring of patients’ daily-life mobility! Interview with Lynn Rochester, Professor of Human Movement Science, Institute of neuroscience, Newcastle University, the Academic Lead of Mobilise-D and Ronenn Roubenoff, Global Head, Translational Medicine Discovery & Profiling, Novartis Institutes for Biomedical Research, the EFPIA Co-lead of Mobilise-D.